By Karen Roman
Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making.
AGO is comprised of gynecological oncologists specialized in breast cancer and interdisciplinary members focused on pathology, radiologic diagnostics, medical oncology and radiation oncology, the company said in a statement.
Agendia’s MammaPrint was included in the AGO guidelines in 2017 to help identify subgroups of patients for potential chemotherapy for breast cancer, while in 2023 it was added to the AGO guidelines for extended endocrine therapy, the company said.
“The insights provided by BluePrint in the neoadjuvant setting help us make decisions in the important early days of diagnosis – a time that is crucial for care teams to have as much information as possible,” said Marc Thill, chief physician of the Clinic for Gynecology and Gynecological Oncology at the Agaplesion Markus Hospital, in Frankfurt.
